Surgery Partners, Inc.
SGRYNASDAQHealthcare● Active
$13.87
+$0.16(+1.18%)
Market Cap$1.8B
P/E Ratio—
52W High$24.1
52W Low$11.41
Surgery Partners, Inc. (SGRY) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
SGRY · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 5, 2026EPS Actual
-$0.03
Est. -$0.15 · +80.0%
Revenue
$0.81B
Est. $0.80B · +1.7%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 5, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 1-Quarter EPS Beat Streak
SGRY reports quarterly as a NASDAQ-listed Medical - Care Facilities company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.07
Rev. $15.39B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.07
Rev. Est.$15.39B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 4, 2026 | $0.01 | — | — | — | $0.83B | — |
| ▲ Q2 FY2026 | May 5, 2026 | -$0.15 | -$0.03 | +80.0% | $0.81B | $0.80B | +1.7% |
| ▼ Q1 FY2026 | Mar 2, 2026 | $0.31 | $0.12 | -61.3% | $0.89B | $0.87B | +2.1% |
| ▼ Q4 FY2025 | Nov 10, 2025 | $0.19 | $0.13 | -31.6% | $0.82B | $0.87B | -5.2% |
| ▲ Q3 FY2025 | Aug 5, 2025 | $0.16 | $0.17 | +6.3% | $0.83B | $0.82B | +0.3% |
| ▼ Q2 FY2025 | May 12, 2025 | $0.08 | $0.04 | -50.0% | $0.78B | $0.78B | -0.1% |
| ▲ Q1 FY2025 | Mar 3, 2025 | $0.38 | $0.44 | +15.8% | $0.86B | $0.80B | +8.0% |
| ▼ Q4 FY2024 | Nov 12, 2024 | $0.25 | $0.19 | -24.0% | $0.77B | $0.83B | -7.1% |
Q3 FY2026
Aug 4, 2026
EPS Actual
—
EPS Est.
$0.01
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 5, 2026Beat
EPS Actual
-$0.03
EPS Est.
-$0.15
EPS Surpr.
+80.0%
Revenue
$0.81B
Q1 FY2026
Mar 2, 2026Miss
EPS Actual
$0.12
EPS Est.
$0.31
EPS Surpr.
-61.3%
Revenue
$0.89B
Q4 FY2025
Nov 10, 2025Miss
EPS Actual
$0.13
EPS Est.
$0.19
EPS Surpr.
-31.6%
Revenue
$0.82B
Q3 FY2025
Aug 5, 2025Beat
EPS Actual
$0.17
EPS Est.
$0.16
EPS Surpr.
+6.3%
Revenue
$0.83B
Q2 FY2025
May 12, 2025Miss
EPS Actual
$0.04
EPS Est.
$0.08
EPS Surpr.
-50.0%
Revenue
$0.78B
Q1 FY2025
Mar 3, 2025Beat
EPS Actual
$0.44
EPS Est.
$0.38
EPS Surpr.
+15.8%
Revenue
$0.86B
Q4 FY2024
Nov 12, 2024Miss
EPS Actual
$0.19
EPS Est.
$0.25
EPS Surpr.
-24.0%
Revenue
$0.77B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.38 | $0.39 | $0.39 | 2 |
| Q3 FY2028 | $0.23 | $0.23 | $0.23 | 2 |
| Q2 FY2028 | $0.17 | $0.17 | $0.17 | 2 |
| Q1 FY2028 | $0.01 | $0.01 | $0.01 | 2 |
| Q4 FY2027 | $0.33 | $0.33 | $0.34 | 1 |
| Q3 FY2027 | $0.19 | $0.19 | $0.19 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $1.0B | $1.0B | $1.0B | 2 |
| Q3 FY2028 | $0.9B | $0.9B | $0.9B | 2 |
| Q2 FY2028 | $0.9B | $0.9B | $0.9B | 2 |
| Q1 FY2028 | $0.9B | $0.9B | $0.9B | 2 |
| Q4 FY2027 | $1.0B | $1.0B | $1.0B | 3 |
| Q3 FY2027 | $0.9B | $0.9B | $0.9B | 3 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 5, 2026 | +80.0% | $14.20 | $14.26 | +0.42% |
| ▼ Q1 FY2026 | Mar 2, 2026 | -61.3% | $15.50 | $15.88 | +2.45% |
| ▼ Q4 FY2025 | Nov 10, 2025 | -31.6% | $21.50 | $16.04 | -25.40% |
| ▲ Q3 FY2025 | Aug 5, 2025 | +6.3% | $22.22 | $22.14 | -0.36% |
| ▼ Q2 FY2025 | May 12, 2025 | -50.0% | $22.16 | $23.26 | +4.96% |
| ▲ Q1 FY2025 | Mar 3, 2025 | +15.8% | $24.08 | $24.00 | -0.33% |
| ▼ Q4 FY2024 | Nov 12, 2024 | -24.0% | $31.43 | $29.57 | -5.92% |
| ▲ Q3 FY2024 | Aug 6, 2024 | +0.0% | $28.72 | $29.64 | +3.20% |
Q2 FY2026+0.42%
Report Date
May 5, 2026
EPS Beat/Miss
+80.0%
Price Before
$14.20
Price After
$14.26
Q1 FY2026+2.45%
Report Date
Mar 2, 2026
EPS Beat/Miss
-61.3%
Price Before
$15.50
Price After
$15.88
Q4 FY2025-25.40%
Report Date
Nov 10, 2025
EPS Beat/Miss
-31.6%
Price Before
$21.50
Price After
$16.04
Q3 FY2025-0.36%
Report Date
Aug 5, 2025
EPS Beat/Miss
+6.3%
Price Before
$22.22
Price After
$22.14
Q2 FY2025+4.96%
Report Date
May 12, 2025
EPS Beat/Miss
-50.0%
Price Before
$22.16
Price After
$23.26
Q1 FY2025-0.33%
Report Date
Mar 3, 2025
EPS Beat/Miss
+15.8%
Price Before
$24.08
Price After
$24.00
Q4 FY2024-5.92%
Report Date
Nov 12, 2024
EPS Beat/Miss
-24.0%
Price Before
$31.43
Price After
$29.57
Q3 FY2024+3.20%
Report Date
Aug 6, 2024
EPS Beat/Miss
+0.0%
Price Before
$28.72
Price After
$29.64
Avg Beat Reaction+0.73%
Avg Miss Reaction-5.98%
Beat Rate4 / 8 quarters
Largest Move-25.40% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: SGRY ends December
Surgery Partners, Inc. (SGRY) most recently reported earnings on May 5, 2026 for Q2 FY2026, posting EPS of $-0.03 — beating the analyst consensus of $-0.15 by +80.0%. The next SGRY earnings date is expected around September 1, 2026.
Each quarter, investors track SGRY earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. SGRY revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
SGRY's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
SGRY earnings · 5 questionsSurgery Partners, Inc.'s next earnings report is expected around September 1, 2026. SGRY typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; SGRY historically reports after market close (AMC).
SGRY earnings datewhen is SGRY earningsSGRY next earnings datewhen does SGRY report earningsSGRY earnings calendar
▸ Source: FMP · Surgery Partners, Inc. SEC filings · US GAAP · Surgery Partners, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026